GeorgiaTuberculosis profile
Population  2016 3.9 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.19 (0.13–0.26) 4.8 (3.4–6.5)
Mortality (HIV+TB only) 0.015 (0.011–0.019) 0.38 (0.28–0.49)
Incidence  (includes HIV+TB) 3.6 (3–4.3) 92 (77–109)
Incidence (HIV+TB only) 0.077 (0.064–0.091) 2 (1.6–2.3)
Incidence (MDR/RR-TB)** 0.78 (0.65–0.92) 20 (17–23)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.21 (0.17–0.24) 1 (0.86–1.2) 1.2 (1–1.5)
Males 0.24 (0.2–0.28) 2.1 (1.8–2.5) 2.4 (2–2.8)
Total 0.45 (0.37–0.52) 3.2 (2.6–3.7) 3.6 (3–4.3)
TB case notifications, 2016  
Total cases notified 3 330
Total new and relapse 2 983
          - % tested with rapid diagnostics at time of diagnosis 81%
          - % with known HIV status 96%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 82% (70–99)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.04–0.08)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 61 2%
          - on antiretroviral therapy 56 92%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  460
(420–500)
Estimated % of TB cases with MDR/RR-TB 11% (9.3–12) 31% (27–35)  
% notified tested for rifampicin resistance 69% 74% 2 348
MDR/RR-TB cases tested for resistance to second-line drugs   329
Laboratory-confirmed cases MDR/RR-TB: 401, XDR-TB: 56
Patients started on treatment **** MDR/RR-TB: 393, XDR-TB: 51
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 84% 2 841
Previously treated cases, excluding relapse, registered in 2015 65% 303
HIV-positive TB cases registered in 2015 69% 71
MDR/RR-TB cases started on second-line treatment in 2014 49% 411
XDR-TB cases started on second-line treatment in 2014 32% 56
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 20%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
30% (28–33)
TB financing, 2017  
National TB budget (US$ millions) 20
Funding source: 32% domestic, 49% international, 19% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-08-15 Data: www.who.int/tb/data